Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Shares are at a 15-month low amid a pile-up of bad news, as analysts call for a course correction, and production woes continue to mount.
Experts testified in one hearing about whether the company had improved safety and compliance procedures since two major crashes.
The figure was enough to push the insurance giant to a loss in Q1, despite its revenue beating expectations.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
The US’ often neglected railways might be on track for better days as the country pumps billions of dollars into outdated infrastructure.
The company’s flagship Modelo brand continues as top dog after surpassing Bud Light in sales last year.
Ford is offering a $1,500 rebate to Tesla owners who may not want to wait around until 2025 for a pricey Cybertruck.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
The company announced positive results in an early-stage trial of the individualized cancer vaccine it developed with Merck.
The filings signal the growing use cases for AI in healthcare settings, but also the risks that may accompany using AI in clinical care.
David Calhoun enjoyed a 45% jump from 2022, but the aerospace giant has started to tie executive pay to broader safety goals.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.